Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +72

Truist Financial Forecasts Strong Price Appreciation for Edwards ...

AI-generated analysis

📈 Truist Financial raised its price target for Edwards Lifesciences to $95.00 from $90.00, projecting a 10.82% upside.

🏆 The company reported Q2 earnings of $0.78 per share, beating analyst estimates by $0.05.

💰 Revenue surged to $1.65 billion, marking a 16.7% increase year-over-year.

📊 Net margins stood strong at 17.39% with a return on equity of 15.19%.

🔮 Management guided for FY 2026 EPS between $2.95 and $3.05, above analyst consensus.

📉 VP Donald E. Bobo, Jr. sold 23,145 shares worth over $2 million in a single transaction.

📈 Royal Bank of Canada increased its target price to $110.00 with an 'outperform' rating.

📈 TD Cowen restated its rating to 'buy' and raised the target price to $104.00.

🏦 Institutional ownership remains robust at 79.46% of total shares outstanding.

📉 Handelsbanken Fonder AB significantly boosted its position by 22.0% in Q2.

❤️ The company specializes in structural heart disease therapies and transcatheter aortic valve replacement (TAVR).

📰 MarketBeat reports the consensus rating is 'Moderate Buy' with an average target of $98.95.

Bullish Signals
  • Truist Financial increased its price target to $95.00, indicating a 10.82% potential upside from current levels.
  • The company beat quarterly earnings estimates by $0.05 per share, reporting $0.78 EPS versus the consensus of $0.73.
  • Revenue grew 16.7% year-over-year to reach $1.65 billion, surpassing analyst expectations of $1.60 billion.
  • Analyst sentiment is broadly positive with a 'Moderate Buy' consensus rating and an average target price of $98.95.
  • Major institutions like Royal Bank of Canada and Mizuho have raised their price targets to $110.00 and $105.00 respectively.
  • TD Cowen upgraded its rating to 'buy' with a new target price of $104.00, up from $97.00.
  • Management provided forward guidance for FY 2026 EPS between $2.95 and $3.05, which exceeds the average analyst forecast of $3.00.
  • Institutional investors are accumulating shares, with Handelsbanken Fonder AB increasing its stake by 22.0% in Q2.
Risk Factors
  • VP Donald E. Bobo, Jr. sold 23,145 shares worth approximately $2 million, reducing his ownership by 19.01%.
  • SVP Andrew M. Dahl also reduced his holdings by selling 568 shares worth roughly $49,000.
Full Analysis
Truist Financial has raised its price target for Edwards Lifesciences (NYSE:EW) from $90.00 to $95.00, citing potential upside of 10.82% from current levels, though maintaining a 'hold' rating. This move aligns with broader analyst sentiment, as the consensus rating remains 'Moderate Buy' with an average target price of $98.95. Other major institutions like Royal Bank of Canada and Mizuho have also recently increased their targets to $110.00 and $105.00 respectively, while TD Cowen upgraded its rating to 'buy' with a $104.00 target. Edwards Lifesciences reported strong financial results for the quarter ended April 23rd, posting earnings per share of $0.78 against consensus estimates of $0.73. Revenue reached $1.65 billion, representing a 16.7% year-over-year increase compared to analyst expectations of $1.60 billion. The company demonstrated robust profitability with a net margin of 17.39% and a return on equity of 15.19%. Management has provided forward guidance for fiscal year 2026 EPS between $2.95 and $3.05, exceeding the average analyst expectation of $3.00. Despite positive financials and analyst upgrades, insider activity shows some executives reducing their stakes. VP Donald E. Bobo, Jr. sold over 2 million dollars worth of shares, while SVP Andrew M. Dahl also reduced his position slightly. However, institutional ownership remains high at 79.46%, with significant increases in holdings from major funds like Handelsbanken Fonder AB and Investors Research Corp during the second quarter, indicating continued confidence in the company's long-term prospects.